Edition:
India

Seelos Therapeutics Inc (SEEL.OQ)

SEEL.OQ on NASDAQ Stock Exchange Capital Market

1.24USD
2:29am IST
Change (% chg)

$-0.06 (-4.62%)
Prev Close
$1.30
Open
$1.29
Day's High
$1.35
Day's Low
$1.23
Volume
81,632
Avg. Vol
67,106
52-wk High
$10.32
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

Seelos Therapeutics Files For Common Stock Offering Of Up To $16.5 Million
Friday, 23 Aug 2019 

Aug 23 (Reuters) - Seelos Therapeutics Inc ::SEELOS THERAPEUTICS INC FILES FOR COMMON STOCK OFFERING OF UP TO $16.5 MILLION - SEC FILING.  Full Article

Seelos Therapeutics Announces FDA Acceptance Of IND Application For SLS-005 For Mucopolysaccharidosis Type III
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - Seelos Therapeutics Inc ::SEELOS THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR SLS-005 FOR MUCOPOLYSACCHARIDOSIS TYPE III (SANFILIPPO SYNDROME).SEELOS THERAPEUTICS INC - FDA ADVISED IT MAY PROCEED WITH PROPOSED CLINICAL TRIAL SLS-005-201 FOR MUCOPOLYSACCHARIDOSIS TYPE III.  Full Article

Ligand Pharma Inc Reports 9.99 Pct Passive Stake In Seelos Therapeutics Inc As Of Feb 27
Tuesday, 16 Apr 2019 

April 15 (Reuters) - Seelos Therapeutics Inc ::LIGAND PHARMACEUTICALS INC REPORTS 9.99 PERCENT PASSIVE STAKE IN SEELOS THERAPEUTICS INC AS OF FEB 27 - SEC FILING.  Full Article

Seelos Therapeutics Files For Offering Of About 16 Mln Shares Of Common Stock
Friday, 8 Mar 2019 

March 8 (Reuters) - Seelos Therapeutics Inc ::SEELOS THERAPEUTICS FILES FOR OFFERING OF ABOUT 16 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Seelos Therapeutics Acquires An Exclusive License To IP Owned By Regents Of University Of California
Thursday, 7 Mar 2019 

March 7 (Reuters) - Seelos Therapeutics Inc ::SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE LICENSE TO INTELLECTUAL PROPERTY FROM THE UC REGENTS TO POTENTIAL DISEASE-MODIFYING PARKINSON'S DISEASE THERAPY CREATED AT UCLA.SEELOS THERAPEUTICS INC - NEW COMPOUND EXPANDS SEELOS' PARKINSON'S PORTFOLIO.SEELOS THERAPEUTICS INC - ACQUIRED AN EXCLUSIVE LICENSE TO INTELLECTUAL PROPERTY OWNED BY REGENTS OF UNIVERSITY OF CALIFORNIA.SEELOS THERAPEUTICS INC - UNDER TERMS OF THIS EXCLUSIVE LICENSE AGREEMENT, SEELOS HAS MADE AN UPFRONT PAYMENT TO UC REGENTS/UCLA OF $100,000.SEELOS THERAPEUTICS INC - NEW PROGRAM WILL BE KNOWN AS SLS-007.SEELOS THERAPEUTICS INC - SEELOS WILL ISSUE FUTURE REMUNERATION IN FORM OF ROYALTIES, WHICH ARE CONTINGENT UPON COMMERCIALIZATION..  Full Article

Seelos Therapeutics Files For Offering Of Up To 15.96 Mln Shares Of Common Stock By The Selling Stockholders
Saturday, 2 Feb 2019 

Feb 1 (Reuters) - Seelos Therapeutics Inc ::SEELOS THERAPEUTICS INC FILES FOR OFFERING OF UP TO 15.96 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Seelos Therapeutics Files For Offering Of Up To 357,573 Shares Of Common Stock By The Selling Stockholders
Saturday, 2 Feb 2019 

Feb 1 (Reuters) - Seelos Therapeutics Inc ::SEELOS THERAPEUTICS INC FILES FOR OFFERING OF UP TO 357,573 SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILINGC.  Full Article

Apricus Biosciences Stockholders Approve Proposed Merger With Seelos Therapeutics
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES STOCKHOLDERS APPROVE PROPOSED MERGER WITH SEELOS THERAPEUTICS, INC..APRICUS BIOSCIENCES INC - OVER 95% OF VOTES CAST WERE IN FAVOR OF MERGER WITH SEELOS.APRICUS BIOSCIENCES INC - OVER 85% OF VOTES CAST WERE IN FAVOR OF REVERSE STOCK SPLIT.  Full Article

Apricus Biosciences Q3 Loss Per Share $0.12
Thursday, 1 Nov 2018 

Oct 31 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE AND THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.  Full Article

Apricus Biosciences Entered Into Purchase Agreement With Investor
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Apricus Biosciences Inc ::APRICUS BIOSCIENCES - ON SEPTEMBER 20, CO ENTERED INTO PURCHASE AGREEMENT WITH AN ACCREDITED INVESTOR - SEC FILING.APRICUS BIOSCIENCES - ENTERED INTO SECURITIES PURCHASE AGREEMENT FOR SALE OF 4.6 MILLION SHARES FOR $0.27 PER SHARE.APRICUS BIOSCIENCES - CLOSING OF SALES OF SECURITIES UNDER PURCHASE AGREEMENT IS EXPECTED TO OCCUR ON SEPT 24, 2018.APRICUS - AGREEMENT ALSO FOR SALE OF WARRANTS TO PURCHASE UP TO 3.45 MILLION AT $0.30/SHARE AND WARRANTS TO PURCHASE 2.7 MILLION SHARES AT $0.40/SHARE.  Full Article